Helicobacter pylori treatment: Is sequential or quadruple therapy the answer?

Reviews in Gastroenterological Disorders

Volumn 8, Issue 2, 2008, Pages 77-82

  Vakil, Nimish ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MARQUETTE UNIVERSITY   (United States)

Author keywords

Amoxicillin; Antibiotics; Bismuth; Clarithromycin; Helicobacter pylori; Metronidazole; Quadruple therapy; Sequential therapy; Tetracycline; Treatment resistance; Triple therapy

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH; BISMUTH CITRATE; BISMUTH SALICYLATE; CLARITHROMYCIN; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG EFFICACY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PENICILLIN ALLERGY; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; TETRACYCLINE; TREATMENT OUTCOME;

EID: 46749148005     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133:985-1001.
2. Bruce MG, Bruden DL, McMahon BJ, et al. Alaska sentinel surveillance for antimicrobial resistance in Helicobacter pylori isolates from Alaska native persons, 1999-2003. Helicobacter. 2006;11:581-588.
3. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. 2004;10:1088-1094.
4. Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998;93:1432-1435.
5. Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter. 2002;7:306-309.
6. De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother. 2007;59:783-785.
7. Koivisto TT, Rautelin HI, Voutilainen ME, et al. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Aliment Pharmacol Ther. 2004;19:1009-1017.
8. Janssen MJ, Hendrikse L, de Boer SY, et al. Helicobacter pylori antibiotic resistance in a Dutch region: trends over time. Neth J Med. 2006;64:191-195.
9. Petersen AM, Gjode P, Vinge OD, et al. Helicobacter pylori antimicrobial resistance and risk factors in Denmark 1998-2004: no need for concern? Helicobacter. 2006;11:210-211.
10. Mohammadi M, Doroud D, Mohajerani N, Massarrat S. Helicobacter pylori antibiotic resistance in Iran. World J Gastroenterol. 2005;11:6009-6013.
11. John Albert M, Al-Mekhaizeem K, Neil L, et al. High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. Aliment Pharmacol Ther. 2006;24:1359-1366.
12. Lwai-Lume L, Ogutu EO, Amayo EO, Kariuki S. Drug susceptibility pattern of Helicobacter pylori in patients with dyspepsia at the Kenyatta National Hospital, Nairobi. East Afr Med J. 2005;82:603-608.
13. Goodwin A, Kersulyte D, Sisson G, et al. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol. 1998;28:383-393.
14. Houben M, van de Beek D, Hensen E, et al. A systematic review of Helicobacter eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999;13:1047-1055.
15. Bochenek WJ, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter. 2003;8:626-642.
16. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99-107.
17. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE Study. Gastroenterology. 2002;123:1763-1769.
18. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98:562-567.
19. O'Morain C, Borody T, Farley A, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther. 2003;17:415-420.
20. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther. 2004;20:1071-1082.
21. Gene E, Calvet X, Azagra R, Gisbert J. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther. 2003;17:1137-1143.
22. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781.
23. Gisbert JP, Gisbert JL, Marcos S, et al. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther. 2005;22:1041-1046.
24. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007;147:553-562.
25. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther. 2003;17:719-726.
26. Hassan C, De Francesco V, Zullo A, et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther. 2003;18:641-646.
27. Focareta R, Forte G, Forte F, et al. Could the 10-days sequential therapy be considered a first choice treatment for the eradication of Heli cobacter pylori infection? Dig Liver Dis. 2003;35(suppl 4):S33.
28. De Francesco V, Della Valle N, Stoppino V, et al. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther. 2004;19:993-998.
29. De Francesco V, Zullo A, Hassan C, et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomized study. Dig Liver Dis. 2004;36:322-326.
30. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007;146:556-563.